12:49 EDT Nuvation Bio (NUVB) jumps 4% to $2.64 after FDA approves Ibtrozi
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB:
- Nuvation Bio’s Strategic Positioning and Potential FDA Approval: Analyst Recommends Buy Rating
- Nuvation Bio Holds Successful Annual Meeting 2025
- Nuvation Bio’s Positive Outlook: Taletrectinib Approval and Financial Strength
- Buy Recommendation for Nuvation Bio: Promising Clinical Results and Strong Financial Position
- Nuvation Bio: Undervalued Growth Potential with Key Developments on the Horizon